Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538630 | 1.00 | REN (0.62) | REN | |
| SCHEMBL8906971 | 1.00 | REN (0.62) | REN | |
| SCHEMBL3752538 | 0.92 | REN (0.64) | REN | |
| SCHEMBL3752535 | 0.92 | REN (0.64) | REN | |
| SCHEMBL8267544 | 0.89 | REN (0.62) | REN | |
| SCHEMBL27975141 | 0.89 | REN (0.62) | REN | |
| SCHEMBL3759583 | 0.88 | REN (0.59) | REN | |
| SCHEMBL3759588 | 0.88 | REN (0.59) | REN | |
| SCHEMBL17770770 | 0.84 | REN (0.61) | REN | |
| SCHEMBL14777723 | 0.83 | REN (0.53) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| JP-8027079-A | — | — | None | — | — | JP | disclosed |
| US-20090318714-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318714-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| JP-H0827079-A | ALPHA-AMINOALKANOIC ACID AND REDUCTION PRODUCT | CIBA GEIGY AG | 1996-01-30 | — | — | JP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318714-A1 | ORGANIC COMPOUNDS | REN, AGTR1, ACE | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.